SeQuent Scientific, Viyash Lifesciences announce merger  

SeQuent Scientific Ltd. which is into animal well being trade and Viyash Lifesciences Personal Ltd., an built-in pharmaceutical firm, have introduced to merge to create a differentiated animal well being firm with end-to-end capabilities. 

Upon the scheme turning into efficient, all shareholders of Viyash will likely be issued shares of SeQuent on the ratio of 56 shares of SeQuent for each 100 shares of Viyash, primarily based on the swap ratio. 

The brand new shares of SeQuent so issued will likely be traded on the NSE and BSE.

Rajaram Narayanan, Managing Director and CEO, SeQuent stated, “We imagine that as a way to proceed to ship differentiated worth to our clients in instances to return, it’s crucial to scale up our product improvement and R&D capabilities to seize the market alternative we’re seeing and to construct on our management within the animal well being market.” 

Haribabu Bodepudi, Chairman and CEO, Viyash, stated, “This merger brings collectively two complementary companies that share a dedication to innovation, operational excellence, and delivering world-class options for our clients. With our mixed sources, R&D capabilities, manufacturing capacities, and streamlined provide chain, we’re well-positioned to speed up progress and supply a wider vary of high-quality merchandise to our clients.”